tiprankstipranks
Trending News
More News >
ProMIS Neurosciences Inc. (PMN)
:PMN
Advertisement

ProMIS Neurosciences (PMN) AI Stock Analysis

Compare
156 Followers

Top Page

PMN

ProMIS Neurosciences

(NASDAQ:PMN)

Rating:38Underperform
Price Target:
ProMIS Neurosciences faces significant financial hurdles, with no current revenue and ongoing operational losses, leading to a weak overall financial performance. The technical analysis indicates the stock is under pressure, and the valuation reflects challenges with a negative P/E ratio. While recent corporate events show promise in terms of future growth potential, they do not offset the immediate financial challenges. The overall score reflects the need for cautious optimism, as the company must improve its financials and achieve sustainable revenue generation.
Positive Factors
Market Potential
The Alzheimer's market presents a massive commercial opportunity, with a potential market exceeding $10 billion annually for an effective anti-amyloid antibody without ARIA risk.
Regulatory Approval
The FDA has granted Fast Track designation to PMN310, potentially accelerating its approval process for treating Alzheimer's disease.
Scientific Advantage
PMN310 shows no binding to amyloid plaque, unlike rival antibodies, potentially reducing the risk of amyloid-related imaging abnormalities (ARIA).
Negative Factors
Cash Reserves
ProMIS has $13.3M in cash on the balance sheet, as well as access to $10.4M on its ATM, which should provide runway through the interim data.
Clinical Development Timeline
The upcoming first-in-patient P1b data in 2026 is a key catalyst and potential proof-of-concept for PMN310.
Financial Concerns
Pipeline seems interesting, but funding is an issue.

ProMIS Neurosciences (PMN) vs. SPDR S&P 500 ETF (SPY)

ProMIS Neurosciences Business Overview & Revenue Model

Company DescriptionProMIS Neurosciences (PMN) is a biotechnology company focused on the discovery and development of precision therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company utilizes its proprietary technology platform to selectively target misfolded proteins implicated in these diseases, aiming to develop disease-modifying treatments. ProMIS Neurosciences operates primarily in the biotechnology and pharmaceutical sectors, leveraging advanced scientific research to address unmet medical needs in neurodegenerative conditions.
How the Company Makes MoneyProMIS Neurosciences generates revenue through a combination of research and development collaborations, licensing agreements, and potential future sales of its proprietary therapeutics. The company may receive upfront payments, milestone payments, and royalties from its partnerships and licensing deals. Additionally, as its products advance through clinical development and potentially receive regulatory approval, ProMIS may earn revenue from product sales. The company's revenue model is highly dependent on successful clinical trials, strategic alliances, and partnerships with larger pharmaceutical companies to commercialize its therapies.

ProMIS Neurosciences Financial Statement Overview

Summary
ProMIS Neurosciences faces significant financial challenges, primarily due to an absence of revenue and consistent operational losses. While the balance sheet shows a strong equity position with no debt, cash flow issues and lack of revenue generation pose risks to long-term financial stability. Efforts to enhance revenue streams and manage cash flows more effectively are essential for improved financial health.
Income Statement
20
Very Negative
ProMIS Neurosciences shows a lack of revenue generation, with total revenue consistently at zero. The company's net profit margin is volatile due to irregular net income figures, and both EBIT and EBITDA margins remain negative, highlighting continued operational losses. The absence of revenue growth is a critical issue.
Balance Sheet
40
Negative
The balance sheet reveals a strong equity position with zero debt, resulting in a stable financial structure. However, the equity ratio fluctuates due to changes in total assets and liabilities. The return on equity is positive in the latest period, but historical volatility suggests instability in earning performance relative to equity.
Cash Flow
30
Negative
The cash flow statement indicates significant negative free cash flow, suggesting cash burn without offsetting revenue. Operating cash flow is consistently negative, reflecting difficulties in generating cash from operations. Despite high financing cash flow, sustainability remains a concern without revenue growth.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.00
Gross Profit0.00-10.44M-21.78M
EBITDA-16.83B-17.81M-29.88M-9.33M
Net Income2.78B-17.51M-12.74M
Balance Sheet
Total Assets18.91M18.04M9.38M22.44M1.38M
Cash, Cash Equivalents and Short-Term Investments13.32M16.75M8.01M21.48M1.11M
Total Debt0.000.000.004.94M0.00
Total Liabilities2.42M13.07M8.68M15.28M2.40M
Stockholders Equity16.49B4.97M7.16M-1.02M
Cash Flow
Free Cash Flow-27.18M-14.37M-17.04M
Operating Cash Flow-27.18M-14.37M-17.03M
Investing Cash Flow-1.98K94.33K
Financing Cash Flow27.88M23.52M6.49M25.20M3.01M

ProMIS Neurosciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.84
Price Trends
50DMA
0.55
Positive
100DMA
0.59
Positive
200DMA
0.77
Positive
Market Momentum
MACD
0.11
Negative
RSI
59.18
Neutral
STOCH
37.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMN, the sentiment is Positive. The current price of 0.84 is above the 20-day moving average (MA) of 0.62, above the 50-day MA of 0.55, and above the 200-day MA of 0.77, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 59.18 is Neutral, neither overbought nor oversold. The STOCH value of 37.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PMN.

ProMIS Neurosciences Risk Analysis

ProMIS Neurosciences disclosed 76 risk factors in its most recent earnings report. ProMIS Neurosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

ProMIS Neurosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$12.08M-83.92%-67.87%0.40%
52
Neutral
$7.58B0.48-62.71%2.36%15.33%0.41%
41
Neutral
$41.55M-161.93%-0.38%
38
Underperform
$27.46M-19.56%98.61%
34
Underperform
$14.69M2.36>-0.01%
30
Underperform
$48.70M-2880.11%31.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PMN
ProMIS Neurosciences
0.84
-0.60
-41.67%
NERV
Minerva Neurosciences
1.91
-1.06
-35.69%
BOLT
Bolt Biotherapeutics
6.13
-8.85
-59.08%
CGTX
Cognition Therapeutics
0.62
-0.38
-38.00%
NRSN
Neurosense Therapeutics Ltd.
1.74
0.98
128.95%

ProMIS Neurosciences Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial
Positive
Feb 25, 2025

On February 25, 2025, ProMIS Neurosciences announced the dosing of multiple patients in its Phase 1b PRECISE-AD clinical trial for PMN310, a drug candidate for Alzheimer’s disease. This milestone highlights the company’s commitment to addressing the urgent need for targeted AD therapies by selectively targeting toxic oligomers, a key driver of disease progression. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of PMN310, with interim results expected in the first half of 2026 and topline results in the second half of 2026. The trial’s design is expected to provide robust clinical data that could differentiate PMN310 from other AD treatments, potentially offering a more effective and well-tolerated option for patients.

Executive/Board ChangesBusiness Operations and Strategy
ProMIS Neurosciences Announces COO Position Termination
Neutral
Feb 19, 2025

On February 14, 2025, ProMIS Neurosciences Inc. announced the separation of Gavin T. Malenfant from his role as Chief Operating Officer, coinciding with the termination of the COO position without plans for a replacement. This move reflects a strategic shift that could impact the company’s operational structure and potential cost-saving measures, influencing both internal efficiencies and external perceptions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025